Pomerantz LLP is investigating securities fraud claims against EyePoint, Inc. following the company's announcement that its Phase 3 clinical trial for DURAVYU failed to meet its primary endpoint against Regeneron's Eylea. The stock plummeted 66.98% to $4.87 per share on August 17, 2026.

Pomerantz LLP is investigating potential securities fraud claims against EyePoint, Inc. following the company's announcement on August 17, 2026, that its DURAVYU drug failed to meet primary endpoints in the LUGANO Phase 3 clinical trial for wet AMD treatment. The failure to demonstrate superiority over Regeneron's Eylea resulted in a 66.98% stock price decline, falling from approximately $14.75 to $4.87 per share.

EyePoint Inc. (NASDAQ: EYPT) announced disappointing Phase 3 clinical trial results for DURAVYU on August 17, 2026, failing to meet its primary endpoint in the LUGANO trial for wet age-related macular degeneration treatment. The stock subsequently dropped over 66%, prompting a securities litigation investigation by KTMC on behalf of affected investors.

EyePoint, Inc. (EYPT) announced its participation in three major investor conferences in September 2026, including Citi Biopharma, Cantor Global Healthcare, and Morgan Stanley Global Healthcare conferences. The company will also present multiple scientific presentations at The Retina Society's 59th Annual Scientific Meeting, focusing on its lead product candidate DURAVYU (vorolanib intravitreal insert) for retinal diseases, including Phase 3 trial data for wet AMD treatment.

EyePoint, Inc. granted non-statutory stock options to three new employees as inducement awards on June 15, 2026. The company granted options to purchase 39,700 shares at an exercise price of $12.08 per share with a ten-year term and four-year vesting schedule. The grants were approved by the Compensation Committee in accordance with NASDAQ regulations.

EyePoint, Inc. (EYPT) announced participation in three upcoming healthcare conferences in May-June 2026. The company also reported a third consecutive positive Data Safety Monitoring Committee (DSMC) recommendation for its Phase 3 wet AMD trials of DURAVYU™, with topline data expected in mid-2026. The trials continue to show a favorable safety profile.

EyePoint announced Q1 2026 financial results with $223 million in cash runway extending into Q4 2027. The company's lead product DURAVYU is progressing through Phase 3 trials for wet AMD and DME, with topline data expected beginning mid-2026 for wet AMD and Q4 2027 for DME. However, net revenue declined significantly to $0.7 million from $24.5 million year-over-year, while operating expenses increased to $87.9 million, resulting in a net loss of $84.8 million.

Cormorant Asset Management sold 50,000 shares of Praxis Precision Medicines (PRAX) in Q4 2025 for $9.31 million, but the position still increased by $227 million in value due to stock appreciation. PRAX remains Cormorant's largest holding at $280 million. The biotech stock has surged 700% over the past year and is advancing multiple late-stage therapies for neurological disorders with strong cash reserves of $926 million.

EyePoint, Inc. (Nasdaq: EYPT) granted non-statutory stock options to purchase 20,000 shares of common stock to six new employees as inducement awards on March 13, 2026, with an exercise price of $13.20 per share. The options vest over four years with a ten-year term. The company continues advancing its lead product DURAVYU in Phase 3 trials for wet AMD and DME, with topline data expected beginning in mid-2026 for wet AMD.

Parkman Healthcare Partners established a new $20 million position in EyePoint Pharmaceuticals by purchasing 1.088 million shares in Q4 2025. EyePoint shares have surged 93% over the past year as the company advances DURAVYU, a sustained-release therapy for retinal diseases, with Phase 3 trial data expected mid-2026. Despite significant losses and development-stage operations, the company has sufficient cash runway into late 2027.

EyePoint, Inc. (Nasdaq: EYPT) announced it will host a conference call on March 4, 2026 to report fourth quarter and full-year 2025 financial results. The clinical-stage biopharmaceutical company is advancing its lead product DURAVYU™, a sustained delivery treatment for retinal diseases, with Phase 3 pivotal trials for wet age-related macular degeneration expected to yield topline data beginning mid-2026, and first patient dosing in diabetic macular edema trials expected in Q1 2026.

EyePoint announced the appointment of Michael Campbell as Chief Commercial Officer, bringing over 30 years of ophthalmology commercial leadership experience. Campbell previously led successful launches of major retinal disease products including Lucentis and Xiidra. He will oversee commercial strategy for DURAVYU, the company's Phase 3 investigational sustained-release treatment for wet AMD and DME, with topline data expected mid-2026.